| 29.07 17:02 | dpa-AFX: *DZ BANK HEBT FAIREN WERT FÜR BRISTOL-MYERS SQUIBB AUF 56 (50) USD - 'KAUFEN' |
| 29.07 17:02 | dpa-AFX: *DZ BANK RAISES FAIR VALUE FOR BRISTOL-MYERS SQUIBB TO 56 (50) USD - 'BUY' |
| 29.07 12:47 | dpa-AFX: ANALYSE-FLASH: Barclays senkt Bristol-Myers Squibb auf 'Underweight' |
| 29.07 12:31 | dpa-AFX: *BARCLAYS CUTS BRISTOL-MYERS SQUIBB TO 'UNDERWEIGHT' (EQUAL W,) - PRICE TARGET 41 USD |
| 29.07 12:31 | dpa-AFX: *BARCLAYS SENKT BRISTOL-MYERS SQUIBB AUF 'UNDERWEIGHT' (EQUAL W.) - ZIEL 41 USD |
| 26.07 15:42 | dpa-AFX: *BRISTOL-MYERS SQUIBB +8,8% - ERHÖHT GEWINNAUSBLICK FÜR 2024 |
| 26.07 13:35 | dpa-AFX: Bristol Myers Squibb Raises 2024 Non-GAAP Guidance |
| 26.07 13:10 | dpa-AFX: *BRISTOL MYERS SQUIBB NOW EXPECTS FY24 NON-GAAP EPS OF $0.60 - $0.90 |
| 26.07 13:09 | dpa-AFX: *BRISTOL MYERS SQUIBB Q2 TOTAL REVENUES $12.201 BLN VS. $11.226 BLN LAST YEAR |
| 26.07 13:08 | dpa-AFX: *BRISTOL MYERS SQUIBB Q2 NET INCOME $1.680 BLN VS. $2.073 BLN LAST YEAR |
| 26.07 13:08 | dpa-AFX: Bristol-Myers Squibb Co. Q2 Profit Decreases, But Beats Estimates |
| 26.07 13:08 | dpa-AFX: *BRISTOL MYERS SQUIBB Q2 NON-GAAP EPS $2.07 VS. $1.75 LAST YEAR |
| 26.07 13:03 | dpa-AFX: *BRISTOL MYERS SQUIBB Q2 EPS $0.83 VS. $0.99 LAST YEAR |
| 26.07 12:00 | dpa-AFX: Bristol-Myers Squibb Q2 24 Earnings Conference Call At 8:00 AM ET |
| 19.07 13:53 | dpa-AFX: Bristol Myers Squibb Receives EMA Validation For Opdivo Plus Yervoy For Treatment Of HCC |
| 19.07 13:13 | dpa-AFX: *BRISTOL MYERS: EMA VALIDATES APPLICATION FOR OPDIVO + YERVOY FOR 1ST-LINE TREATMENT OF UNRESECTABLE OR ADVANCED HEPATOCELLULAR CARCINOMA |
| 10.07 09:52 | dpa-AFX: *BARCLAYS SENKT ZIEL FÜR BRISTOL-MYERS SQUIBB AUF 41 (43) USD - 'EQUAL WEIGHT' |
| 10.07 09:52 | dpa-AFX: *BARCLAYS CUTS BRISTOL-MYERS SQUIBB PRICE TARGET TO 41 (43) USD - 'EQUAL WEIGHT' |
| 18.06 22:21 | dpa-AFX: *BRISTOL MYERS SQUIBB ELECTS MICHAEL MCMULLEN TO BOARD OF DIRECTORS |
| 18.06 13:10 | dpa-AFX: *BRISTOL-MYERS SQUIBB CO. (BMY) DECLARES QUARTERLY DIVIDEND OF $ 0.60, RECORD DATE 7/5/2024 |
|
|
